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a  b  s  t  r  a  c  t
The  “gold  standard”  for  post-mortem  rabies  diagnosis  is  the  direct  ﬂuorescent  antibody  test  (FAT).  How-
ever, in  the  case  of  ante-mortem  non-neural  sample  material  or  decomposed  tissues,  the  FAT  reaches  its
limit,  and the use of  molecular  techniques  can  be advantageous.  In  this  study,  we  developed  and  vali-
dated a reverse  transcription  PCR  cascade  protocol  feasible  for the classiﬁcation  of  samples,  even  those  for
which  there  is no epidemiological  background  knowledge.  This  study  emphasises  on  the  most  relevant
European  lyssaviruses.
In  a ﬁrst  step,  two independent  N- and  L-gene  based  pan-lyssavirus  intercalating  dye  assays  are per-
formed  in  a double-check  application  to  increase  the  method’s  diagnostic  safety.  For the  second  step,
characterization  of the  lyssavirus  positive  samples  via  two  independent  multiplex  PCR-systems  was  per-
formed. Both  assays  were  probe-based,  species-speciﬁc  multiplex  PCR-systems  for Rabies  virus,  European
bat  lyssavirus  type  1 and  2 as well  as  Bokeloh  bat  lyssavirus.  All  assays  were  validated  successfully  with
a  comprehensive  panel  of lyssavirus  positive  samples,  as well  as  negative  material  from  various  host
species.
This double-check  strategy  allows  for both  safe  and  sensitive  screening,  detection  and  characterization
of  all  lyssavirus  species  of  humans  and  animals,  as  well  as  the rapid  identiﬁcation  of currently  unknown
lyssaviruses  in bats in Europe.
ublis© 2014  The  Authors.  P
. Introduction
Although rabies has been known since antiquity, it still repre-
ents one of the most important zoonotic diseases with an immense
ublic health impact, especially in developing countries (Knobel
t al., 2005; Anderson and Shwiff, 2013). The causative agents of
his fatal encephalitis are lyssaviruses (order Mononegavirales, fam-
ly Rhabdoviridae), with the prototype species being Rabies virus
RABV). Further members of the genus Lyssavirus are Lagos bat
irus (LBV), Mokola virus (MOKV), Duvenhage virus (DUVV), Euro-
ean bat lyssavirus type 1 and 2 (EBLV-1 & -2), Australian bat
∗ Corresponding author. Tel.: +49 0 38351 71201; fax: +49 0 38351 7 1226.
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166-0934/© 2014 The Authors. Published by Elsevier B.V. This is an open access article uhed  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/3.0/).
lyssavirus (ABLV), Aravan virus (ARAV), Khujand virus (KHUV), Irkut
virus (IRKV), West Caucasian bat virus (WCBV), and Shimoni bat virus
(SHIBV) (Dietzgen et al., 2012). The two most recently discovered
lyssaviruses, Bokeloh bat lyssavirus (BBLV) and Ikoma virus (IKOV)
(Freuling et al., 2011; Marston et al., 2012), are approved as new
lyssavirus species and are awaiting ratiﬁcation by the International
Committee on Taxonomy of Viruses. Bats appear to be the orig-
inal reservoir for lyssaviruses, and many of those bat-associated
viruses have caused human fatalities worldwide (Johnson et al.,
2010; Banyard et al., 2011). However, the vast majority of human
exposures and consequently fatalities are related to RABV, which
is transmitted by dog bites (WHO, 2013).
The “gold standard” method for rabies diagnosis that is rec-
ommended by the World Health Organization (WHO) and the
Organization for Animal Health (OIE) is the direct ﬂuorescent
nder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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ntibody test (FAT; Dean et al., 1996; OIE, 2008). This method facil-
tates the detection of lyssavirus antigens in post-mortem brain
pecimens (Dürr et al., 2008; Fooks et al., 2009). Though, for ante-
ortem diagnosis in humans using non-neural sample material
e.g., saliva, cerebrospinal ﬂuid, skin biopsies) or in the case of
ecomposed tissues, the FAT reaches its limits. Additionally, with
espect to passive bat rabies surveillance, post-mortem laboratory
iagnosis is often hampered by such difﬁculties as obtaining sufﬁ-
ient and good quality brain material. Furthermore, serial and fully
utomated testing of larger sample numbers, e.g., for screening
urposes in bats, is not possible using the FAT.
Although not yet recommended for routine post-mortem diag-
osis of rabies, in such situations, including epidemiological
urveys, the use of molecular methods, such as reverse tran-
cription PCR (RT-PCR) and other ampliﬁcation techniques, can
e advantageous (David et al., 2002; Dacheux et al., 2010; WHO,
013). As a result, numerous pan-lyssavirus or lyssavirus species-
peciﬁc conventional and real-time RT-PCRs have been developed
for details see Fooks et al., 2009; Coertse et al., 2010; Hoffmann
t al., 2010). Because of the ability of real-time PCRs, to detect
mall amounts of viral RNA, these assays have become the method
f choice for molecular diagnostics of infectious agents, including
abies, over the past decade (Hoffmann et al., 2009; Coertse et al.,
010).
To improve the overall diagnostic possibilities, we  developed
 cascade protocol for molecular lyssavirus diagnostics with an
mphasis on the most relevant European lyssaviruses. As a ﬁrst
tep, two independent pan-lyssavirus assays based on the detec-
ion of an intercalating dye are performed in a double-check
pplication to increase diagnostic reliability. If a lyssavirus is rec-
gnized (“positive result”), as a second step, two  probe-based
TaqMan), species-speciﬁc multiplex systems for RABV, EBLV-1,
BLV-2 and BBLV detection are applied to determine the virus
pecies. Additionally, using this procedure, samples without any
urther epidemiological background information can be detected
nd classiﬁed.
. Material and methods
.1. Pan-lyssavirus and species-speciﬁc PCRs
To detect various lyssavirus species reliably, one pan-lyssavirus
pan-Lyssa) real-time RT-PCR (RT-qPCR) described recently by
ayman et al. (2011) and one newly developed RT-qPCR, with both
sing the OneStep RT-PCR Kit (Qiagen, Hilden, Germany), target-
ng regions in the nucleoprotein (N) and large (L, RNA dependent
olymerase) gene, respectively, were applied in parallel. The assays
ere optimized for limited sample material using a total reac-
ion volume of 12.5 l. For one reaction, 5.5 l RNase-free water,
.5 l 5x OneStep RT-PCR Buffer, 0.5 l OneStep RT-PCR Enzyme
ix, 0.5 l dNTP Mix  (10 mM each), 0.5 l ResoLight Dye (Roche,
annheim, Germany), 0.25 l of each primer (Table 1) and 2.5 l
NA template or RNase free water for the no template control (NTC)
as used. Functionality of ampliﬁcation was tested in an extra
ube using the heterologous internal control (IC) system developed
y Hoffmann et al. (2006) in combination with the endogenous
ousekeeping assay according to Toussaint et al. (2007; Table 1)
s extraction control. For the heterologous internal control, 0.25 l
C2 RNA (Hoffmann et al., 2006) per reaction was spiked in the PCR
eaction mix. The following thermal program was  applied: 1 cycle
f 50 ◦C for 30 min  and 95 ◦C for 15 min, followed by 45 cycles of
4 ◦C for 30 s, 56 ◦C for 30 s and 72 ◦C for 30 s. Subsequently, melt
urve analysis was performed (1 min  95 ◦C, 1 min  55 ◦C, increase
.5 ◦C per cycle for 10 s; 55–95 ◦C) for the veriﬁcation of positive
esults (Supplementary Table 1). Validity ranges of the meltingal Methods 203 (2014) 23–32
temperature (Tm) were deﬁned for the pan-Lyssa N-gene RT-
qPCR (Tm 77.5 ± 1.5 ◦C) and the pan-Lyssa L-gene RT-qPCR (Tm
82 ± 1.5 ◦C). Final conﬁrmation was achieved by sequencing, using
the respective primers and the Big Dye Terminator v1.1 Cycle
Sequencing Kit (Applied Biosystems, Carlsbad, USA).
For lyssavirus species-speciﬁc detection, the AgPath-IDTM One-
Step RT-PCR Kit (Applied Biosystems, Carlsbad, USA) was used by
combining the assay developed by Wakeley et al. (2005; R13 MP)
with a novel FLI multiplex (R14 MP)  assay both targeting the N-gene
of lyssaviruses. Both assays were optimized using a total reaction
volume of 12.5 l. Furthermore, the published assay by Wakeley
et al. (2005) was  extended by an additional BBLV probe (Table 1).
For one single reaction, 2.75 l (R13 MP)  or 1.25 l (R14 MP)  RNase-
free water, 6.25 l 2x RT-PCR buffer, 0.5 l 25x RT-PCR enzyme mix,
2.5 l RNA template or RNase free water for the no template con-
trol (NTC) and 0.5 l of the according primer–probe mixes (Table 1)
were combined. The following thermal program was applied: 1
cycle of 45 ◦C for 10 min  and 95 ◦C for 10 min, followed by 45 cycles
of 95 ◦C for 15 s, 56 ◦C for 20 s, and 72 ◦C for 30 s.
All reactions were carried out as technical duplicates in Bio-Rad
96-well PCR plates using a CFX96 quantitative PCR system (Bio-Rad
Laboratories, Hercules, USA). For each RT-qPCR, a quantiﬁcation
cycle number (Cq) was determined according to the PCR cycle num-
ber at which the ﬂuorescence of the reaction crosses a value that
is statistically higher than the background which is determined by
the respective software associated with each system. Finally, mean
Cq-values were calculated from the technical duplicates. A cut off
>42 was deﬁned for negative results.
2.2. Generation of a synthetic positive control
For repeatability analysis, a synthetic gene was designed includ-
ing positive controls for all lyssavirus assays used in this study
(Supplementary Table 2). The construct was synthesized by Gen-
eArt (GeneArt, Regensburg, Germany) with the vector pMA-7-Ar
as a backbone (Supplementary Fig. 1). Plasmids were ampli-
ﬁed in Escherichia coli DH10B (Invitrogen, Carlsbad, USA) and
puriﬁed by Qiagen Plasmid Mini and Midi Kits (Qiagen, Hilden,
Germany) according to standard protocols. The identity of the plas-
mids was conﬁrmed by NotI-digestion, gel electrophoresis and
sequencing using the Big Dye Terminator v1.1 Cycle Sequencing Kit
(Applied Biosystems, Carlsbad, USA). Linearized and puriﬁed plas-
mid  DNA was in vitro transcribed with the RiboMAX Large Scale
RNA Production Systems (Promega, Mannheim, Germany), and a
DNase I digestion was  performed subsequently using the SP6/T7
Transcription Kit (Roche, Mannheim, Germany) according to the
manufacturer’s instructions. During puriﬁcation of the in vitro tran-
scribed RNA using the RNeasy Mini Kit (Qiagen, Hilden, Germany),
a second on-column DNase I digestion according to the manufac-
turer’s recommendations was  implemented. The exact number of
RNA molecules was  calculated as described (Hoffmann et al., 2005),
and a log10 dilution series (2 × 106 to 2 × 10−1 copies per l) was
prepared in RNA-safe buffer (RSB; Hoffmann et al., 2006). To inves-
tigate matrix effects, a 20% (w/v) suspension of negative wolf brain
was prepared, and RNA was extracted in two  independent runs
using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to
the manufacturer’s instructions. The artiﬁcial positive control was
spiked in the extracted matrix as ﬁnal log10 dilutions of 2 × 106 to
2 × 10−1 copies per l. RNA was  stored until use at −20 ◦C.
2.3. ValidationAnalytical sensitivity was  determined for the pan-lyssavirus
RT-qPCR systems by using a deﬁned positive spiking control
(Tables 2A and 2B). Therefore, full genome RABV (sample ID
5989) was spiked in 20% (w/v) negative wolf brain suspension
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Table  1
Oligonucleotide sequences and composition of primer–probe mixes used in this study.
PCR assay Primer/Probe Sequence (5′–3′) Position Concentration
[M]b
Referencec
Pan-lyssavirus
N-gene PCR
JW12 ATG TAA CAC CYC TAC AAT G 55–73d 20
Hayman et al. (2011)
N165-146 GCA GGG TAY TTR TAC TCA TA 165–146d 20
L-gene PCR
Pan-Lyssa-7531F TTC TTC GCT YTR ATG TCW TGG AA 7074–7096d 20
This study
Pan-Lyssa-7749R ATG RTT GTT CCA CTT YTC ATA RTC 7292–7269d 20
Lyssavirus-speciﬁc
R13  MP
JW12 ATG TAA CAC CYC TAC AAT G 55–73d 10
Wakeley et al. (2005)
mod.
N165-146 GCA GGG TAY TTR TAC TCA TA 165–146d 10
LysGT1-FAM FAM-ACA AGA TTG TAT TCA AAG TCA ATA ATC AG-BHQ1 81–109d 2.5
LysGT5-HEX HEX-AA CAR GGT TGT TTT YAA GGT CCA TAA-BHQ1 80–105d 2.5
LysGT6-Cy5 Cy5-ACA RAA TTG TCT TCA ARG TCC ATA ATC AG-BHQ3 81–109d 2.5
BBLV-1TEX TEX-CTC TGA CAA GAT TGT CTT CAA AGT C-BHQ2 76–101d 2.5
R14  MP
RV-N-196-F GAT CCT GAT GAY GTA TGT TCC TA 266–288d 10
Hoffmann et al. (2010)RV-N-283-R RGA TTC CGT AGC TRG TCC A 353–335d 10
RabGT1-B-FAM FAM-CAG CAA TGC AGT TYT TTG AGG GGA C-BHQ1 297–321d 2.5
R14  MP
EBLV1-353F GCT CAA ACR GGA GGT CAA GA 431–450e 10
this studyEBLV1-440R AGA CAR AGA AGA AGT CCW ACC A 510–489e 10
EBLV1-392HEX HEX-ACC CTA CRA CAC CTG AAC ATG CAT CT-BHQ1 462–487e 2.5
R14  MP
EBLV2-42F RGT GTC TGT AAA RCC AGA AG 112–131f 15
Schatz et al. (2013)
mod.
EBLV2-173R GAC AGA ATR GAC TTA TAA GCT CT 243–221f 15
EBLV2N Probe Cy5-TCG GAA AAA ACC CAG CAT AAC CCT-BHQ2 175–198f 2.5
R14
MP
BBLV-2F CCT TGG TRA ACA TTC AGA GAA CG 390–412g 10
Freuling et al. (2013)
mod.
BBLV-2R GGC CAC AGT TGG ATC CCT TG 475–456g 10
BBLV-2TEX as TEX-TCC TCC GGT CAA GGC CCA RTT GCC-BHQ2 422–445g 2.5
Internal controlsa
ICh
EGFP1-F GAC CAC TAC CAG CAG AAC AC 637–656h 2.5
Hoffmann et al. (2006)EGFP2-R GAA CTC CAG CAG GAC CAT G 768–750h 2.5
EGFP-Probe 1 FAM-AGC ACC CAG TCC GCC CTG AGC A-BHQ1 703–724h 1.25
ICe
ACT-1005-F CAG CAC AAT GAA GAT CAA GAT CAT C 1005–1029i 2.5
Toussaint et al. (2007)ACT-1135-R CGG ACT CAT CGT ACT CCT GCT T 1135–1114i 2.5
ACT-1081-HEX HEX-TCG CTG TCC ACC TTC CAG CAG ATG T-BHQ1 1081–1105i 1.25
a ICh: heterologous internal control, ICe: endogenous internal control.
b Applied concentration for the reaction.
c mod.: original assay was  modiﬁed for this study.
d Reference Pasteur virus (M13215).
e Reference EBLV-1 (EF157976).
f Reference EBLV-2 (EF157977).
a
t
t
1
d
t
a
r
n
T
E
r
n
2g Reference BBLV (JF311903).
h Reference cloning vector pEGFP-1 (U55761).
i Reference beta actin sequences (AY141970, U39357).
s ﬁnal log10 dilutions of 1 × 104.45 to 1 × 10−3.45 50% tissue cul-
ure infectious doses per ml  (TCID50 ml−1). RNA was extracted in
wo independent runs per sample (biological duplicates), eluted in
00 l RNase free water and stored until use at −20 ◦C. Biological
uplicates were tested by each pan-lyssavirus RT-qPCR system in
hree independent runs. The limit of detection (LOD) was  deﬁned
s the virus titer, giving a positive RT-qPCR result in 95% of the
epeats (Vandemeulebroucke et al., 2010). Coefﬁcient of determi-
ation (R2) values were calculated by the CFX manager software 3.0
able 2A
valuation of the analytical sensitivity of the positive spiking control (RABV 5989)
egarding the pan-Lyssa N-gene RT-qPCR.
Titera Mean (n = 12)b SDc CV (%)d
1 × 104.45 19.5 0.23 1.20
1  × 103.45 22.8 0.26 1.16
1  × 102.45 26.2 0.14 0.55
1 × 101.45 29.8 0.30 1.01
1  × 100.45 33.1 0.27 0.82
1 × 10−1.45 36.7 0.52 1.41
1  × 10−2.45 no Cq – –
1  × 10−3.45 no Cq – –
a Titer of positive spiking control in TCID50 ml−1.
b Mean value of 12 replicates (biological and technical replicates of three runs),
o Cq: no Cq-value detected.
c SD: standard deviation.
d CV: coefﬁcient of variation calculated according to Vandemeulebroucke et al.,
010; –: no value available.(Bio-Rad Laboratories, Hercules, USA). The coefﬁcient of variation
(CV) was  calculated according to Vandemeulebroucke et al. (2010)
[CV = standard deviation/mean Cq value of all replicates]. Further-
more, for the pan-lyssavirus RT-qPCR systems, the positive spiking
control was  compared to the artiﬁcial positive control spiked in
extracted negative brain matrix or diluted in RSB (Supplementary
Table 3).
Moreover, assay efﬁciencies of the pan-lyssavirus RT-
qPCR systems were determined for RABV, EBLV-1, EBLV-2
Table 2B
Evaluation of the analytical sensitivity of the positive spiking control (RABV 5989)
regarding the pan-Lyssa L-gene RT-qPCR.
Titera Mean (n = 12)b SDc CV (%)d
1 × 104.45 22.6 0.24 1.06
1  × 103.45 26.4 0.25 0.95
1  × 102.45 29.6 0.25 0.85
1  × 101.45 34.3 0.22 0.65
1  × 100.45 37.5 0.28 0.74
1  × 10−1.45 40.3 0.33 0.82
1  × 10−2.45 no Cq – –
1  × 10−3.45 no Cq – –
a Titer of positive spiking control in TCID50 ml−1.
b Mean value of 12 replicates (biological and technical replicates of three runs),
no Cq: no Cq-value detected.
c SD: standard deviation.
d CV: coefﬁcient of variation calculated according to Vandemeulebroucke et al.,
2010; –: no value available.
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Table  3A
Double-check analysis of viral genome detection via pan-lyssavirus RT-qPCRs.
Sample IDa Virus species Materialb Hostc,d Year of isolationc Origin pan-Lyssa
N-gene PCRe
pan-Lyssa
L-gene PCRe
IChf ICeg
122 RABV BS fox 2005 Romania 28.9 29.6 25.6 38.1
132  RABV BS domestic cat 2005 Romania 25.9 27.1 25.7 39.0
1390  RABV TCS fox 1998 Germany 35.0 40.0 26.2 40.2
5989  RABV BS dog 2002 Azerbaijan 26.3 27.5 25.8 36.7
11164 RABV BS fox 2005 Germany 25.6 26.4 25.5 39.9
11240  RABV BS human 2005 Germany 29.3 31.7 25.7 38.9
11317 RABV BS raccoon dog 1990 Estonia 31.9 33.0 25.8 37.0
11318 RABV BS fox 1981 Norway 25.1 29.9 25.8 38.5
11321 RABV BS fox 1995 Bulgaria 28.8 30.7 25.9 37.1
11322 RABV BS dog 1979 Pakistan 25.3 25.9 25.9 35.1
11329 RABV BS dog 1988 Nigeria 23.1 26.6 26.0 37.4
11332 RABV BS dog 1982 India 21.6 21.8 25.9 38.5
11333 RABV BS dog 1981 Mexico 24.5 26.3 25.7 38.1
12887 RABV BS raccoon dog 1986 Poland 34.9 39.3 25.8 41.8
12909  RABV BS fox 1993 Poland 25.5 26.1 25.7 40.2
12952 RABV BS fox 2001 Estonia 36.1 35.2 25.6 39.3
13001  RABV TCS raccoon dog 1991 Estonia 35.7 35.3 25.9 41.2
13044  RABV TCS fox 1990 Saudi Arabia 36.2 33.0 25.8 N/A
13056  RABV BS dog 1984 Turkey 28.2 30.2 25.7 36.8
13077  RABV BS fox 1995 Bulgaria 32.5 33.7 25.9 38.5
13078  RABV BS human 1995 Bulgaria 25.1 25.0 25.8 36.4
13079  RABV BS fox 1995 Bulgaria 33.0 36.1 25.8 39.6
13088  RABV BS dog 1979 Pakistan 23.8 24.7 25.8 35.1
13118 RABV BS dog 1983 Algeria 34.1 30.9 25.9 41.9
13160  RABV TCS sheep 1991 Iran 31.4 29.5 25.9 N/A
13164 RABV TCS hyaena 1991 Iran 39.9 35.6 25.8 N/A
13213 RABV TCS skunk 1981 USA 29.0 30.2 25.8 40.3
13240  RABV BS – 1986 Canada 32.3 28.1 25.8 38.5
FN  RABV BS fox – Romania 27.6 29.2 25.6 36.8
12865  EBLV-1 BS bat (E. serotinus) 1968 Germany 36.3 28.8 25.6 35.3
25438  EBLV-1 OS (p.m.) bat 1997 Germany 34.9 32.2 25.6 35.0
25768  EBLV-1 OS (bladder) bat (E. serotinus) 2011 Germany 40.4 37.2 25.9 37.2
25969  EBLV-1 OS (s.g.) bat (E. serotinus) 2009 Germany 23.6 21.0 25.9 38.5
25978  EBLV-1 OS (p.m.) bat (E. serotinus) 2010 Germany 38.9 34.5 25.5 34.4
27932  EBLV-1 OS (heart) bat (E. serotinus) 2006 Germany 35.9 29.9 25.2 36.2
27987  EBLV-1 OS (testis) bat (E. serotinus) 2011 Germany 33.0 31.5 25.6 35.4
27988  EBLV-1 OS (tongue) bat (E. serotinus) 2011 Germany 28.9 28.8 25.5 36.2
28113  EBLV-1 BS bat (E. serotinus) – Denmark 34.2 25.6 25.6 36.4
28119  EBLV-1 TCS – 1993 Denmark 27.4 18.4 25.7 39.0
28120  EBLV-1 TCS – 1994 Denmark 34.4 28.2 25.8 41.6
13034  EBLV-1 BS bat (E. serotinus) 1987 The Netherlands 34.8 32.3 25.8 35.6
13037  EBLV-1 BS bat (E. serotinus) 1987 The Netherlands 27.0 25.6 25.8 37.6
12950  EBLV-2 BS human 1985 Finland 30.0 37.6 25.6 38.9
25538  EBLV-2 TCS bat (M.  daubentonii) 2006 Germany 35.3 40.8 25.8 41.6
13035  EBLV-2 BS bat (E. serotinus) 1987 The Netherlands 27.1 33.3 25.6 36.5
13036  EBLV-2 BS bat (M.  dasycneme) 1987 The Netherlands 24.3 32.8 25.5 34.3
BH  51/10 BBLV BS bat (M.  nattereri) 2010 Germany 28.9 26.5 25.9 33.5
29029  BBLV TCS bat (M.  nattereri) 2012 Germany 41.0 31.1 25.8 34.3
GH235 LBV BS bat (E. helvum) 2012 Ghana 36.5 28.2 25.6 34.6
12858  MOKV TCS dog 1992 Ethiopia 41.3 29.6 25.6 39.6
12869 DUVV TCS – 1984 Germany 31.8 30.1 25.7 N/A
13849  ABLV TCS bat Australia 31.9 36.5 25.6 40.5
BH  62/13-28 neg. BS fox 2011 Germany N/A N/A 25.4 32.3
BH  62/13-29 neg. BS badger 2009 Germany N/A N/A 25.5 32.4
BH  62/13-53 neg. BS polecat (ﬁtch) 2009 Germany N/A N/A 25.6 30.5
BH  62/13-54 neg. BS raccoon dog 2010 Germany N/A N/A 25.7 33.0
BH  62/13-113 neg. BS mink 2010 Germany N/A N/A 25.8 31.5
BH  62/13-114 neg. BS pine marten 2010 Germany N/A N/A 25.6 32.3
BH  62/13-144 neg. BS stone marten 2011 Germany N/A N/A 25.4 30.3
BH  23/13-8 neg. serum raccoon 2012 Germany N/A N/A 26.1 31.9
25371  neg. OS (tongue) bat (P. auritus) 2011 Germany N/A N/A 25.8 37.5
25372  neg. OS (heart) bat (P. auritus) 2011 Germany N/A N/A 25.7 35.3
GH233 neg. BS bat (E. helvum) 2012 Ghana N/A N/A 25.8 34.6
a Standard face 1:1000 dilution, bold face 1:100, italics 1:5 dilution of original RNA.
b BS: brain sample, TCS: tissue culture supernatant, OS: organ suspension, p.m.: pectoral muscle, s.g.: salivary gland.
c –: no information available.
d E. helvum: Eidolon helvum; E. serotinus: Eptesicus serotinus; M. dasycneme: Myotis dasycneme; M.  daubentonii: Myotis daubentonii; M.  nattereri: Myotis nattereri; P. auritus:
Plecotus auritus.
e N/A: no Cq-value available.
f ICh: heterologous internal control.
g ICe: endogenous internal control; columns 7–10 represent mean Cq-values from duplicates.
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Table  3B
Virus characterization via double-check multiplex RT-qPCR systems.
Sample IDa Virus speciesb R13 MPc R14 MPc
RABV EBLV-1 EBLV-2 BBLV RABV EBLV-1 EBLV-2 BBLV
122 RABV 26.6 N/A N/A N/A 26.6 N/A N/A N/A
132  RABV 24.1 N/A N/A N/A 24.7 N/A N/A N/A
1390  RABV 32.3 N/A N/A N/A 31.8 N/A N/A N/A
5989  RABV 25.7 N/A N/A N/A 25.9 N/A N/A N/A
11164  RABV 25.6 N/A N/A N/A 23.3 N/A N/A N/A
11240  RABV 27.9 N/A N/A N/A 30.4 N/A N/A N/A
11317  RABV 30.5 N/A N/A N/A 30.9 N/A N/A N/A
11318  RABV 23.9 N/A N/A N/A 28.0 N/A N/A N/A
11321  RABV 27.5 N/A N/A N/A 27.7 N/A N/A N/A
11322  RABV 24.2 N/A N/A N/A 29.6 N/A N/A N/A
11329  RABV 20.9 N/A N/A N/A N/A N/A N/A N/A
11332  RABV 20.7 N/A N/A N/A 26.1 N/A N/A N/A
11333  RABV 22.8 N/A N/A N/A 23.7 N/A N/A N/A
12887  RABV 33.1 N/A N/A N/A 34.6 N/A N/A N/A
12909  RABV 25.7 N/A N/A N/A 29.2 N/A N/A N/A
12952  RABV 34.1 N/A N/A N/A 33.6 N/A N/A N/A
13001 RABV 33.7 N/A N/A N/A 33.8 N/A N/A N/A
13044  RABV 31.3 N/A N/A N/A 31.4 N/A N/A N/A
13056  RABV 26.2 N/A N/A N/A 28.3 N/A N/A N/A
13077  RABV 30.3 N/A N/A N/A 30.1 N/A N/A N/A
13078  RABV 24.0 N/A N/A N/A 23.8 N/A N/A N/A
13079  RABV 31.7 N/A N/A N/A 31.3 N/A N/A N/A
13088  RABV 22.9 N/A N/A N/A 28.2 N/A N/A N/A
13118  RABV 30.8 N/A N/A N/A 29.4 N/A N/A N/A
13160  RABV 28.9 N/A N/A N/A 28.0 N/A N/A N/A
13164  RABV 36.2 N/A N/A N/A 37.8 N/A N/A N/A
13213  RABV 26.5 N/A N/A N/A 26.3 N/A N/A N/A
13240  RABV N/A N/A N/A N/A 30.1 N/A N/A N/A
FN  RABV 26.1 N/A N/A N/A 26.4 N/A N/A N/A
12865  EBLV-1 N/A 30.2 N/A N/A N/A 28.2 N/A N/A
25438  EBLV-1 N/A 30.6 N/A N/A N/A 29.9 N/A N/A
25768  EBLV-1 N/A 34.4 N/A N/A N/A 33.8 N/A N/A
25969  EBLV-1 N/A 20.7 N/A N/A N/A 20.3 N/A N/A
25978  EBLV-1 N/A 33.3 N/A N/A N/A 32.2 N/A N/A
27932  EBLV-1 N/A 28.7 N/A N/A N/A 27.3 N/A N/A
27987  EBLV-1 N/A 30.2 N/A N/A N/A 28.5 N/A N/A
27988  EBLV-1 N/A 27.0 N/A N/A N/A 25.8 N/A N/A
28113  EBLV-1 N/A 26.7 N/A N/A N/A 22.6 N/A N/A
28119  EBLV-1 N/A 21.3 N/A N/A N/A 16.2 N/A N/A
28120  EBLV-1 N/A 27.8 N/A N/A N/A 23.6 N/A N/A
13034  EBLV-1 N/A 30.2 N/A N/A N/A 29.2 N/A N/A
13037  EBLV-1 N/A 23.8 N/A N/A N/A 23.4 N/A N/A
12950  EBLV-2 N/A N/A 28.4 N/A N/A N/A 28.7 N/A
25538  EBLV-2 N/A N/A 34.0 N/A N/A N/A 33.4 N/A
13035  EBLV-2 N/A N/A 25.9 N/A N/A N/A 26.1 N/A
13036  EBLV-2 N/A N/A 22.8 N/A N/A N/A 23.5 N/A
BH  51/10 BBLV 27.4d N/A 27.4d 26.7 N/A N/A N/A 23.0
29029  BBLV 34.6d N/A 34.5d 33.8 N/A N/A N/A 27.2
GH235 LBV N/A N/A N/A N/A N/A N/A N/A N/A
12858  MOKV N/A N/A N/A N/A N/A N/A N/A N/A
12869  DUVV N/A N/A N/A N/A N/A N/A N/A N/A
13849  ABLV N/A N/A N/A N/A N/A N/A N/A N/A
BH  62/13-28 neg. N/A N/A N/A N/A N/A N/A N/A N/A
BH  62/13-29 neg. N/A N/A N/A N/A N/A N/A N/A N/A
BH  62/13-53 neg. N/A N/A N/A N/A N/A N/A N/A N/A
BH  62/13-54 neg. N/A N/A N/A N/A N/A N/A N/A N/A
BH  62/13-113 neg. N/A N/A N/A N/A N/A N/A N/A N/A
BH  62/13-114 neg. N/A N/A N/A N/A N/A N/A N/A N/A
BH  62/13-144 neg. N/A N/A N/A N/A N/A N/A N/A N/A
BH  23/13-8 neg. N/A N/A N/A N/A N/A N/A N/A N/A
25371  neg. N/A N/A N/A N/A N/A N/A N/A N/A
25372  neg. N/A N/A N/A N/A N/A N/A N/A N/A
GH233 neg. N/A N/A N/A N/A N/A N/A N/A N/A
a Standard face 1:1000 dilution, bold face 1:100, italics 1:5 dilution of original RNA.
m dup
a
t
T
sb neg.: lyssavirus negative material.
c N/A: no Cq-value available.
d Cross-reactivity for BBLV samples; columns 3–10 represent mean Cq-values fro
3.45nd BBLV. Therefore, the positive spiking control (1 × 10
o 1 × 10−4.45 TCID50 ml−1), EBLV-1 (1 × 103.75 to 1 × 10−4.75
CID50 ml−1) and EBLV-2 (1 × 103.17 to 1 × 10−4.17 TCID50 ml−1)
amples extracted from brain suspension spiked with full genomelicates.
−2 −8virus as well as BBLV RNA (1 × 10 to 1 × 10 ) diluted in RSB
were analyzed (Supplementary Fig. 2). The respective efﬁciencies
were calculated according to Vandemeulebroucke et al. (2010)
[PCR efﬁciency (%) = 100 × (101/slope − 1)], where the slope was
28
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Table 4
Results of the inter-laboratory validation.
Sample ID (laba) Virus species Materialb Host Year of
isolation
Originc Dilutiond pan-Lyssa
N-gene PCR
pan-Lyssa
L-gene PCR
IChe ICef R13
MPg
R14
MPg
RABV EBLV-1 EBLV-2 BBLV RABV EBLV-1 EBLV-2 BBLV
08017359 (CVI) EBLV-1 BS bat 2008 NL undil. 17.8 13.2 25.0 32.1 N/A 17.8 N/A N/A N/A 14.6 N/A N/A
11014118 (CVI) EBLV-1 BS bat 2011 NL undil. 17.6 14.2 25.0 28.5 N/A 16.7 N/A N/A N/A 16.0 N/A N/A
11014798 (CVI) EBLV-1 BS bat 2011 NL undil. 18.2 13.5 24.7 29.5 N/A 17.0 N/A N/A N/A 15.0 N/A N/A
11014831 (CVI) EBLV-1 BS bat 2011 NL undil. 15.0 13.1 25.2 27.0 N/A 13.6 N/A N/A N/A 14.5 N/A N/A
12009493 (CVI) EBLV-1 BS bat 2012 NL undil. 17.7 14.9 24.6 28.2 N/A 16.7 N/A N/A N/A 15.5 N/A N/A
12014060 (CVI) EBLV-1 BS bat 2012 NL undil. 15.5 11.5 24.7 27.2 N/A 14.9 N/A N/A N/A 12.3 N/A N/A
12014718 (CVI) EBLV-1 BS bat 2012 NL undil. 15.7 11.9 24.6 27.6 N/A 15.2 N/A N/A N/A 13.4 N/A N/A
12019333 (CVI) EBLV-1 BS bat 2012 NL undil. 17.9 13.3 24.9 29.3 N/A 19.5 N/A N/A N/A 15.2 N/A N/A
PC  2 × 104 – IVT – – – 2 × 104 21.5 24.1 25.0 – 22.6 21.7 21.9 21.4 21.3 21.2 20.6 21.8
PC  2 × 103 – IVT – – – 2 × 103 24.3 27.4 25.6 – 25.4 24.2 24.6 24.0 24.1 24.4 23.4 24.6
PC  2 × 102 – IVT – – – 2 × 102 28.2 31.0 24.9 – 28.8 27.6 28.2 27.8 27.6 27.6 26.5 27.9
Gra  7/10 (DTU) RABV BS polar foxh 2010 GL undil. 11.1 17.4 24.6 19.3 18.8 N/A N/A N/A 14.6 N/A N/A N/A
Gra  1/13 (DTU) RABV BS polar foxh 2013 GL undil. 13.8 15.7 25.1 19.0 19.1 N/A N/A N/A 19.2 N/A N/A N/A
Gra  2/13 (DTU) RABV BS polar foxh 2013 GL undil. 12.5 15.3 25.1 18.8 17.0 N/A N/A N/A 17.5 N/A N/A N/A
Gra  3/13 (DTU) RABV BS polar foxh 2013 GL undil. 13.4 14.7 24.8 20.8 17.4 N/A N/A N/A 18.1 N/A N/A N/A
Ra  8/06 (DTU) EBLV-1 BS bat 2006 DK 1:100 23.4 23.2 24.8 29.3 N/A 23.9 N/A N/A N/A 22.6 N/A N/A
Ra  8/06 (DTU) EBLV-1 BS bat 2006 DK 1:1000 27.3 27.6 25.2 32.8 N/A 27.9 N/A N/A N/A 26.0 N/A N/A
Ra  32/03 (DTU) EBLV-1 BS bat 2003 DK undil. 26.9 22.9 24.6 31.1 N/A 28.5 N/A N/A N/A 26.3 N/A N/A
Ra  34/03 (DTU) EBLV-1 BS bat 2003 DK undil. 28.1 23.7 24.8 31.0 N/A 28.6 N/A N/A N/A 26.7 N/A N/A
Ra  5/09 (DTU) EBLV-1 BS bat 2009 DK undil. 11.8 11.2 24.8 23.3 N/A 13.7 N/A N/A N/A 13.1 N/A N/A
PC  2 × 104 – IVT – – – 2 × 104 21.5 24.4 25.1 – 23.7 24.5 21.9 22.7 22.1 23.7 20.9 23.5
PC  2 × 103 – IVT – – – 2 × 103 24.5 27.9 24.8 – 27.0 27.5 25.2 25.9 25.2 26.4 23.7 26.3
PC  2 × 102 – IVT – – – 2 × 102 27.7 31.2 25.0 – 29.4 29.6 27.7 28.2 28.0 29.1 26.2 28.5
a CVI: Central Veterinary Institute of Wageningen UR, DTU: Technical University of Denmark – National Veterinary Institute, PC: artiﬁcial positive control.
b BS: brain sample, IVT: in vitro transcript.
c NL: The Netherlands, GL: Greenland, DK: Denmark.
d undil.: undiluted, dilution of PC given as copies per l.
e ICh: heterologous internal control.
f ICe: endogenous internal control.
g N/A: no Cq-value available; –: no information available; columns 8–19 represent mean Cq-values from duplicates.
h Polar fox (Vulpes lagopus).
ological Methods 203 (2014) 23–32 29
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Table 5
Validation of the endogenous internal control system.
Different material typesa Cq range beta actin
Liver (n = 327) 23–26
Spleen (n = 1) 23–26
Kidney (n = 2) 23–26
Lung (n = 1) 23–26
Brain (n = 158) 28–30
Samples
∑
n = 489
a Sample material was obtained from 9 different species: fox (Vulpes vulpes,
n  = 192), badger (Meles meles, n = 27), raccoon (Procyon lotor, n = 28), raccoon dogM. Fischer et al. / Journal of Vir
valuated by the CFX manager software 3.0. Additionally, the
ntra-assay repeatability of all applied systems was determined
sing four replicates of the log10 dilution series of the artiﬁcial
ositive control (2 × 106 to 2 × 10−1 copies per l). The inter-assay
epeatability was assessed for the same dilution series on four sep-
rate days. Standard deviations (SD) and box plots were generated
y R software (R Foundation for Statistical Computing, 2011).
For determination of diagnostic speciﬁcity, a reference panel
f 52 selected lyssavirus positive samples, consisting of 29 RABV
trains from different countries and different host species as well
s LBV, MOKV, DUVV, ABLV, BBLV, EBLV-1 and EBLV-2 samples
Table 3A), was used. Furthermore, speciﬁcity evaluation was per-
ormed with lyssavirus negative bat and carnivore sample materials
s well as cell culture material of related rhabdoviruses, i.e., Vesic-
lar stomatitis Indiana virus (VSV Ind), Vesicular stomatitis New
ersey virus (VSV NJ), Bovine ephemeral fever virus (BEFV) and
iral hemorrhagic septicemia virus (VHSV) (Supplementary Table
). According to sample quantity, RNA was extracted manually
sing the RNeasy Mini Kit (Qiagen, Hilden, Germany) according
o the manufacturer’s instructions or was extracted using the King
isher 96 Flex (Thermo Scientiﬁc, Braunschweig, Germany) in com-
ination with the MagAttract Virus Mini M48  Kit (Qiagen, Hilden,
ermany) according to the manufacturer’s instructions. RNA was
luted in 100 l RNase free water and stored until use at −20 ◦C.
ilutions of the original RNA were performed in RSB, ensuring sta-
ility of the nucleic acid (Fischer et al., 2013; Table 3B).
Finally, an inter-laboratory validation was performed in two
dditional cooperating laboratories, located in the Netherlands and
n Denmark, using samples from their respective archives and log10
ilutions (2 × 104 to 2 × 102 copies per l) of the synthetic positive
ontrol (Table 4).
. Results
In the ﬁrst step of the diagnostic cascade, both applied pan-
yssavirus RT-qPCR systems were able to recognize all lyssavirus
ositive samples (Table 3A; Supplementary Fig. 3). However, dif-
erences in the sensitivity were recognized between the two
ystems. Notably, the pan-Lyssa N-gene RT-qPCR displayed a supe-
ior sensitivity for the RABV samples “1390” from Germany and
11318” from Norway as well as all tested EBLV-2 and ABLV iso-
ates. Whereas, for RABV samples from the Middle East countries
audi Arabia (“13044”) and Iran (“13160”, “13164”) as well as
rom Canada (“13240”), the pan-Lyssa L-gene RT-qPCR seemed to
e more sensitive. Furthermore, the pan-Lyssa L-gene RT-qPCR
emonstrated a considerably increased sensitivity for all analyzed
BLV-1, BBLV, MOKV and DUVV samples in contrast to the pan-
yssa N-gene RT-qPCR. Both pan-Lyssa RT-qPCR systems scored
egative for all of the negative material in the validation panel
Supplementary Fig. 3). Furthermore, rhabdovirus isolates of VSV
J, VSV Ind, BEFV and VHSV were analyzed for speciﬁcity testing
sing both pan-lyssavirus RT-qPCRs. The pan-Lyssa N-gene RT-
PCR scored negative for all tested isolates. The pan-Lyssa L-gene
T-qPCR displayed a positive result solely for the VSV NJ isolate
Supplementary Table 4).
The application of the heterologous internal control (ICh,
able 3A) according to Hoffmann et al. (2006) demonstrated
he functionality of ampliﬁcation during PCR. The heterologous
NA was detected with approximately 26 Cq-values, as described
reviously (Hoffmann et al., 2006), which indicates that there
ere no PCR inhibitors present. The endogenous internal controlICe) was not analysable for the test panel due to the pre-dilution
100–1000-fold) of the original RNA, producing artiﬁcial results.
owever, the endogenous internal control system was validated
reliminarily for different sample matrices (e.g., brain or liver)(Nyctereutes procyonoides, n = 39), marten (Martes, n = 8), stone marten (Martes foina,
n  = 20), pine marten (Martes martes, n = 30), mink (Mustela lutreola, n = 26), polecat
(Mustela putorius, n = 2).
using various undiluted negative carnivore sample materials
(Table 5). Obtained data were analyzed according to matrix types.
For the matrices of liver, spleen, kidney and lung, a Cq range of
23–26 was  deﬁned. Brain material yielded a Cq range of 28–30,
indicating minor inhibitory effects for undiluted samples. This
issue was also observed for both pan-lyssavirus RT-qPCR systems
by comparing a log10 dilution series of the artiﬁcial positive control
diluted in RSB to a dilution series of the artiﬁcial positive control
spiked in negative brain matrix, yielding increased Cq-values for the
positive control spiked in matrix material compared to the positive
control without matrix background (Supplementary Table 3).
In the second line, the multiplex assays R13 MP and R14 MP  dis-
played a widely comparable sensitivity for RABV isolates, except for
samples “11322” and “13088” from Pakistan, “11332” from India,
“11318” from Norway and “12909” from Poland, where the R13
MP system was  superior (Table 3B). In exchange, the R14 MP  assay
demonstrated a higher sensitivity for the recognition of EBLV-1 and
BBLV. Some of the RABV-isolates were only recognized by one sys-
tem (sample “11329” – R13 MP  only; sample “13240” – R14 MP
only). Furthermore, both systems displayed equal sensitivities for
EBLV-2 detection (e.g., sample “12950”: 28.4 in R13 MP  and 28.7 in
R14 MP;  sample “13035”: 25.9 in R13 MP  and 26.1 in R14 MP). Addi-
tionally, differences in the BBLV differentiation capabilities became
obvious as the RABV and EBLV-2 speciﬁc probes of the R13 MP  assay
showed cross-reactivity with both BBLV-isolates whereas the R14
MP assay displayed an optimal speciﬁcity (reaction occurred solely
with the BBLV probe). Both multiplex PCR-systems scored negative
for LBV, MOKV, DUVV, ABLV, and all negative control materials.
Concerning analytical sensitivity, both pan-Lyssa RT-qPCR
assays displayed a detection limit of 1 × 10−1.45 TCID50 ml−1 for the
positive spiking control (Tables 2A and 2B). Furthermore, standard
deviations were low (0.14–0.52 for the pan-Lyssa N-gene RT-qPCR
and 0.22–0.33 for the pan-Lyssa L-gene RT-qPCR), and the coef-
ﬁcient of variation (CV) ranged from 0.55% to 1.41% (pan-Lyssa
N-gene RT-qPCR) or 0.65% to 1.06% (pan-Lyssa L-gene RT-qPCR),
indicating low variation between the replicates. The coefﬁcient of
determination (R2) and assay efﬁciency (E) were determined for
three independent runs as 0.993 to 0.996 (R2) and 92% to 94% (E)
for the pan-Lyssa N-gene RT-qPCR as well as 0.993 to 0.998 (R2)
and 85% to 89% (E) for the pan-Lyssa L-gene RT-qPCR. Furthermore,
assay efﬁciencies determined for EBLV-1, EBLV-2 and BBLV, ranged
from 80% to 89% for the pan-Lyssa N-gene RT-qPCR and from 74%
to 88% for the pan-Lyssa L-gene RT-qPCR (ampliﬁcation plots see
Supplementary Fig. 2).
A comparison among the positive spiking control and the arti-
ﬁcial positive control with and without brain matrix background
revealed a high concordance among Cq-values obtained from dilu-
tions of the positive spiking control and the artiﬁcial positive
control with matrix background in both pan-Lyssa RT-qPCR assays
(Supplementary Table 3). The artiﬁcial positive control without
matrix background yielded lower Cq-values. The overall detection
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Fig. 1. Repeatability analysis of the pan-lyssavirus real-time RT-PCR assays. (A) pan-Lyssa N-gene RT-qPCR and (B) pan-Lyssa L-gene RT-qPCR were investigated using a
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aog10 dilution series of the positive control. Cq-Values from 16 replicates are shown
oftware  (R Foundation for Statistical Computing, 2011).
anges however, were the same for the artiﬁcial positive control
ith and without brain matrix background (2 × 106 to 2 × 100
opies per l for the pan-Lyssa N-gene RT-qPCR and 2 × 106 to × 101 copies per l for the pan-Lyssa L-gene RT-qPCR). Repeat-
bility analysis was performed for all assays using the artiﬁcial
ositive control. Mean Cq-values and standard deviations for intra-
ssay and inter-assay repeatability are shown in Figs. 1 and 2.
ig. 2. Repeatability analysis of the applied species-speciﬁc multiplex real-time RT-PCR
B  + F), EBLV-2 (C + G) and BBLV (D + H) was investigated using a log10 dilution series of the
re  stated in parentheses. Box plots were designed supported by R software (R Foundatiodard deviations are stated in parentheses. Box plots were designed supported by R
In general, all applied systems displayed excellent repeatability.
Regarding the multiplex assays, detection ranges from 2 × 106 to 2
copies per l for RABV or EBLV-2 as well as 2 × 106 to 20 copies per
l for EBLV-1 or BBLV were observed (Fig. 2).
The samples applied for the inter-laboratory validation
(Table 4), predominantly EBLV-1 specimens, were detected cor-
rectly by both pan-lyssavirus RT-qPCR systems. As observed before,
 systems. (A–D) R13 MP and (E-H) R14 MP.  The detection of RABV (A + E), EBLV-1
 positive control. Cq-Values from 16 replicates are shown each. Standard deviations
n for Statistical Computing, 2011).
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he pan-lyssavirus L-gene RT-qPCR displayed higher sensitivity for
BLV-1 detection. Application of the endogenous and heterologous
nternal control systems ensured that no RNA-extraction or ampli-
cation failure occurred. Species differentiation using the R13 MP
nd R14 MP  assays was  also successful for all samples (Table 4).
urthermore, both laboratories yielded concordant Cq-values for
he provided dilutions of the artiﬁcial positive control.
. Discussion
Although numerous molecular techniques have been developed
or lyssavirus detection, the diversity of this genus implies cer-
ain limitations, especially concerning their diagnostic range (Fooks
t al., 2009; Coertse et al., 2010; Hoffmann et al., 2010). There-
ore, regarding lyssaviruses, a continuous modiﬁcation of molecular
etection methods is necessary (Coertse et al., 2010). Nevertheless,
o ultimate approach or strategy has been established to date, that
ould facilitate routine rabies diagnosis or epidemiological surveys
n molecular grounds. Recent WHO  research needs for molecu-
ar diagnostic methods for lyssaviruses called for more universal
rimers, real-time RT-PCR assays and improved protocols to cover
he diversity of lyssaviruses and to improve diagnostic reliability
WHO, 2013). Therefore, we developed a novel two  level cascade
olecular diagnostics protocol using lyssaviruses known to circu-
ate in Europe as a proof of principle. Our study focused on highly
ensitive TaqMan real-time reverse transcription PCRs.
Initially, two independent pan-lyssavirus RT-qPCR systems
ere applied using a double-check strategy. The nucleoprotein (N)
ene targeting pan-Lyssa N-gene RT-qPCR is based on the protocol
y Hayman et al. (2011) whereas the pan-Lyssa L-gene RT-qPCR is
 novel system targeting a conserved region on the polymerase (L)
ene spanning the more highly conserved regions at the end and the
eginning of the two major functional blocks II and III, respectively
Poch et al., 1990). Both pan-Lyssa RT-qPCRs detected all posi-
ive samples of a broad panel with partially different sensitivities
Tables 3A and 4). Interestingly, the pan-Lyssa N-gene RT-qPCR pro-
ided better performance for EBLV-2 and ABLV detection, whereas
he pan-Lyssa L-gene RT-qPCR was superior for EBLV-1, BBLV, LBV,
OKV and DUVV recognition. This observation strongly supports
he idea of the initial application of this double check strategy
here one assay is able to balance the impairment of the corre-
ponding assay, thereby increasing both diagnostic sensitivity and
eliability. In the case of a doubtful result, melt curve analysis can
e consulted to avoid a false positive result due to the formation of
rimer dimers. Speciﬁcity analysis revealed a positive result for a
SV NJ isolate in the pan-Lyssa L-gene RT-qPCR (Supplementary
able 4). Due to this impairment of speciﬁcity, we  recommend
onﬁrmation of positive samples by sequencing. Nevertheless,
uring the development of this generic L-gene based assay, the
ocus was on coverage of an extremely broad detection range for
yssaviruses to facilitate the recognition of novel, phylogenetic dis-
ant species.
Subsequently, pan-Lyssa RT-qPCR positive samples were sub-
ected to the testing with real-time RT-PCRs for the rapid
dentiﬁcation of European lyssavirus species. For species-speciﬁc
etection of RABV, EBLV-1, EBLV-2 and BBLV, the published
ultiplex system by Wakeley et al. (2005) was extended by a BBLV-
peciﬁc probe (R13 MP). The basis for the R14 MP system is the
ublished R14 assay by Hoffmann et al. (2010), which was  edited
ith in-house primer probe sets for EBLV-1, EBLV-2 and BBLV
etection (Table 1). The sensitivity of RABV and EBLV-2 recogni-
ion was widely comparable between both multiplex PCR-systems
Table 3B). However, differences were observed regarding BBLV
ifferentiation capabilities. The R13 MP  assay, using one universal
rimer pair, appears to be user-friendly; unfortunately, this issueal Methods 203 (2014) 23–32 31
also leads to a limitation of the system. The narrow location of the
universal primers conﬁnes the sequence region for probe position-
ing, which adversely affects the speciﬁcity and averts an arbitrary
expansion of the system. The novel R14 MP  assay however, applies
a separate primer–probe-set for the detection of each species.
All applied assays scored negative for all of the negative con-
trol materials, suggesting notably high speciﬁcity of the assays
against various host species. Moreover, all four systems displayed
excellent repeatability (Figs. 1 and 2). Evaluation of the analytical
sensitivity using a RABV positive spiking control revealed high sen-
sitivity for both generic pan-Lyssa RT-qPCR assays with a detection
limit of 1 × 10−1.45 TCID50 ml−1 (Tables 2A and 2B). Furthermore,
both generic systems displayed sufﬁcient assay efﬁciencies for
RABV, EBLV-1, EBLV-2 and BBLV. Additionally, good concordance,
regarding Cq-values, was observed between the positive spiking
control and the artiﬁcial positive control with matrix background
(Supplementary Table 3).
Further advantages of this novel cascade workﬂow are the ﬂex-
ibility according to the sample materials as well as the rapidity and
the reduced risk of cross-contamination due to the closed tube,
non-nested format in comparison to nested or hemi-nested RT-
PCR protocols (for details see Fooks et al., 2009; Coertse et al.,
2010). Thus, the presented cascade workﬂow combines all known
advantages of real-time PCR technology with the improved safety
of molecular testing based on a double-check strategy for the ﬁrst-
level screening as well as second-level conﬁrmation assays. The
cascade protocol is adapted for the screening, detection and charac-
terization of all lyssavirus species relevant for humans and animals
in Europe. However, the described workﬂow could be modiﬁed eas-
ily for other parts of the world, e.g., Africa, Asia or Australia, where
next to RABV, other bat associated lyssaviruses are known to exist,
provided that appropriate and optimized real-time RT-PCRs for
the second level cascade are available. For ARAV, KHUV, IRKV and
ABLV, real-time RT-PCRs have been described (Foord et al., 2006;
Hughes et al., 2006). A one-step quantitative real-time PCR assay
utilizing a single primer–probe set for the detection of a diverse
panel of four African lyssaviruses (RABV, MOKV, LBV, DUVV) was
developed recently (Coertse et al., 2010). However, for individual
African lyssaviruses (MOKV, LBV, DUVV, SHIBV, IKOV) and WCBV,
species-speciﬁc assays are still missing. Under the condition of
pan-lyssavirus positive and species-speciﬁc real-time RT-PCR neg-
ative results, the suggested molecular diagnostic cascade approach
might even be able to detect (i) not currently isolated lyssaviruses,
such as Lleida bat lyssavirus (LLEBV; Aréchiga Ceballos et al., 2013),
(ii) lyssaviruses that do not circulate in a particular region, or (iii)
unknown bat associated lyssaviruses. Ultimately, this diagnostic
cascade applying a real-time RT-PCR double-check strategy rep-
resents the highest molecular diagnostic standard available as a
routine discriminatory and conﬁrmatory test for rabies diagnosis.
Depending on the speciﬁc diagnostic question, e.g., bat lyssavirus
screening, and depending on the availability of resources, the indi-
vidually validated assays may  be separately used and/or combined
to obtain a molecular diagnostic strategy ﬁt for this purpose.
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